核苷(酸)类似物治疗慢性乙型肝炎急性发作的效果观察

阮建文; 高丽娟; 苏汝开; 王亚娇; 杨京

doi:10.3969/j.issn.1001-5256.2019.06.014

核苷(酸)类似物治疗慢性乙型肝炎急性发作的效果观察

DOI: 10.3969/j.issn.1001-5256.2019.06.014

1. 中南大学湘雅医学院附属海口医院感染科
2. 贵州医科大学附属医院感染科

基金项目:

海南省卫生计生行业科研项目(18A200094)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 456
- HTML全文浏览量: 48
- PDF下载量: 91
- 被引次数: 0
出版历程
- 收稿日期: 2018-12-10
- 出版日期: 2019-06-20

Clinical effect of nucleos (t) ide analogues in treatment of acute exacerbation of chronic hepatitis B

Department of Infectious Diseases, Haikou Hospital Affiliated to Xiangya School of Medicine, Central South University

Research funding:

摘要

摘要: 目的探讨核苷（酸）类似物（NAs）治疗慢性乙型肝炎（CHB）急性发作48周的临床效果。方法选取2014年10月-2018年7月中南大学湘雅医学院附属海口医院诊治的HBeAg阳性CHB和HBeAg阴性CHB患者。其中ALT> 10倍正常值上限的CHB急性发作患者48例,为试验组; ALT <10×ULN且TBil <5×ULN的CHB患者51例,为对照组。2组患者均接受恩替卡韦和替诺福韦酯治疗。分析比较试验组和对照组经NAs治疗的临床过程和效果,观察指标包括基线时肝功能、HBV DNA、HBsAg、抗-HBs、HBeAg、抗-HBe和肝脏超声检查,并在治疗第12、24、48周进行随访评估。符合正态分布的计量资料2组间比较采用t检验,非正态分布的计量资料2组间比较采用Mann-Whitney U检验。计数资料2组间比较采用χ2检验或Fisher精确检验。结果试验组患者在12、24、48周的ALT复常率分别为89. 58%、93. 75%、93. 75%,与对照组患者的49. 02%、72. 55%、76. 47%相比,差异均有统计学意义（χ...
- 肝炎,乙型,慢性 /
- 核苷类 /
- 核苷酸类 /
- 治疗结果 /
- 回顾性研究
Abstract: Objective To investigate the clinical effect of nucleos (t) ide analogues (NAs) in the treatment of acute exacerbation of chronic hepatitis B (CHB) for 48 weeks. Methods The CHB patients with positive or negative HBeAg who were diagnosed and treated in Haikou Hospital Affiliated to Xiangya School of Medicine, Central South University, from October 2014 to July 2018 were enrolled. Among these patients, 48 with an acute exacerbation of CHB and an alanine aminotransferase (ALT) level of > 10 × upper limit of normal (ULN) were enrolled as experimental group, and 51 with an ALT level of < 10 × ULN and a total bilirubin level of < 5 × ULN were enrolled as control group. Both groups were treated with entecavir and tenofovir disoproxil fumarate. The two groups were compared in terms of the clinical process and outcome of NA treatment, including baseline liver function, HBV DNA, HBsAg, anti-HBs, HBeAg, anti-HBe, and liver ultrasound findings, and follow-up was performed at weeks 12, 24, and 48 of treatment. The t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups. The chi-square test or the Fisher's exact test was used for comparison of categorical data between two groups.Results There was a significant difference in ALT normalization rate at weeks 12, 24, and 48 of treatment between the experimental group and the control group (89. 58%/93. 75%/93. 75% vs 49. 02%/72. 55%/76. 47%, χ2= 18. 917, 7. 814, and 5. 743, all P < 0. 05) .There was a significant difference in the undetectable rate of HBV DNA at week 12 of treatment between the experimental group and the control group (83. 33% vs 60. 78%, χ2= 6. 198, P = 0. 013) , while there was no significant difference between the two groups at weeks 24 and48 of treatment (95. 83%/95. 83% vs 84. 31%/86. 27%, P > 0. 05) . There was a significant difference in HBeAg seroconversion rate between the experimental group and the control group at weeks 12, 24, and 48 of treatment (23. 26%/25. 58%/27. 91% vs 2. 22%/2. 22%/8. 89%, χ2= 8. 894, 10. 188, and 5. 346, all P < 0. 05) . Clearance or seroconversion of HBsAg was not observed in the experimental group or the control group. Conclusion NAs can achieve high ALT normalization rate, HBV DNA undetectable rate, and HBeAg seroconversion rate in the treatment of patients with acute exacerbation of CHB.
- hepatitis B, chronic /
- nucleosides /
- nucleotides /
- treatment outcome /
- retrospective studies

HTML全文

参考文献(23)

[1]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[2]CHANG ML, LIAW YF.Hepatitis B flares in chronic hepatitis B:Pathogenesis, natural course, and management[J].JHepatol, 2014, 61 (6) :1407-1417.

[3]PONDRA.Acute hepatitis B virus infection or acute exacerbation of chronic hepatitis B infection:The differential serological diagnosis[J].Eur J Clin Microbiol Infect Dis, 2016, 35 (1) :29-40.

[4]TSAI WL, SUN WC, CHENG JS.Chronic hepatitis B with spontaneous severe acute exacerbation[J].Int J Mol Sci, 2015, 16 (12) :28126-28145.

[5]PURI P.Acute exacerbation of chronic hepatitis B:The dilemma of differentiation from acute viral hepatitis B[J].J Clin Exp Hepatol, 2013, 3 (4) :301, 312.

[6]XIE GJ, ZHANG HY, CHEN Q, et al.Changing etiologies and outcome of liver failure in Southwest China[J].Virol J, 2016, 13:89.

[7]CAI Q, CHEN F, SHAO X, et al.Treatment of pegylated interferon-alpha2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation[J].Antivir Ther, 2015, 20 (2) :217-224.

[8]LIN S, YE Q, WANG M, et al.Antiviral therapy in chronic hepatitis B with mild acute exacerbation[J].Gastroenterology Res, 2017, 10 (1) :6-14.

[9]YU W, ZHAO C, SHEN C, et al.The efficacy and safety of nucleos (t) ide analogues in patients with spontaneous acute exacerbation of chronic hepatitis B:A systematic review and meta-analysis[J].PLo S One, 2013, 8 (6) :e65952.

[10]HUNG CH, HU TH, LU SN, et al.Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation[J].Antimicrob Agents Chemother, 2015, 59 (6) :3168-3173.

[11]HUANG KW, TAM KW, LUO JC, et al.Efficacy and safety of lamivudine versus entecavir for treating chronic hepatitis B virus-related acute exacerbation and acute-on-chronic liver failure:A systematic review and meta-analysis[J].J Clin Gastroenterol, 2017, 51 (6) :539-547.

[12]BERTOLETTI A, FERRARI C.Adaptive immunity in HBV infection[J].J Hepatol, 2016, 64 (1 Suppl) :s71-s83.

[13]YE B, LIU X, LI X, et al.T-cell exhaustion in chronic hepatitis B infection:Current knowledge and clinical significance[J].Cell Death Dis, 2015, 6:e1694.

[14]FERRARI C, BONI C, ROSSI M, et al.T cell regulation in HBV-related chronic liver disease[J].J Hepatol, 2017, 66 (5) :1096-1098.

[15]RUAN JW, GAO LJ, SU RK.Clinical features of patients with acute exacerbation of chronic hepatitis B:An analysis of 74cases[J].J Clin Hepatol, 2016, 32 (11) :2096-2098. (in Chinese) 阮建文, 高丽娟, 苏汝开.74例慢性乙型肝炎患者急性发作临床特征分析[J].临床肝胆病杂志, 2016, 32 (11) :2096-2098.

[16]YU HM, KWON SY, KIM J, et al.Virologic response and safety of tenofovir versus entecavir in treatment-na6ve chronic hepatitis B patients[J].Saudi J Gastroenterol, 2015, 21 (3) :146-151.

[17]TONG S, REVILL P.Overview of hepatitis B viral replication and genetic variability[J].J Hepatol, 2016, 64 (1 Suppl) :s4-s16.

[18]LI Q, HUANG YX, CHEN L.Simple serum markers for significant liver inflammation in chronic hepatitis B patients with an alanine aminotransferase level lower than 2 times upper limit of normal[J].J Clin Hepatol, 2016, 32 (6) :1125-1129. (in Chinese) 李强, 黄玉仙, 陈良.ALT小于2倍正常值上限的慢性乙型肝炎患者显著肝脏炎症的简易血清标志物探索[J].临床肝胆病杂志, 2016, 32 (6) :1125-1129.

[19]LI W, XU KH, ZHAO SS.Association between liver pathology and clinical features in patients with chronic HBV infection and slightly elevated alanine aminotransferase[J].J Clin Hepatol, 2017, 33 (11) :2123-2126. (in Chinese) 李伟, 徐葵花, 赵守松.ALT轻度升高的慢性HBV感染者临床特征与病理学的关系[J].临床肝胆病杂志, 2017, 33 (11) :2123-2126.

[20]KANDA T, SHINOZAKI M, KAMEZAKI H, et al.Efficacy of lamivudine or entecavir on acute exacerbation of chronic hepatitis B[J].Int J Med Sci, 2012, 9 (1) :27-32.

[21]YASUI S, FUJIWARA K, NAKAMURA M, et al.Virological efficacy of combination therapy with corticosteroid and nucleoside analogue for severe acute exacerbation of chronic hepatitis B[J].J Viral Hepat, 2015, 22 (2) :94-102.

[22]CHEN CH, LIN CL, HU TH, et al.Entecavir vs lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation[J].J Hepatol, 2014, 60 (6) :1127-1134.

[23]HUNG CH, KEE KM, CHEN CH, et al.A randomized controlled trial of glycyrrhizin plus tenofovir vs.tenofovir in chronic hepatitis B with severe acute exacerbation[J].Clin Transl Gastroenterol, 2017, 8 (6) :e104.

施引文献

资源附件(0)

访问统计